M1 Kliniken AG AI Stock Analysis
Want to see DE:M12 full AI Analyst Report?
M1 Kliniken AG (M12) AI Stock Analysis
M1 Kliniken AG
(XETRA:M12)
M1 Kliniken earns an above-average score driven primarily by solid fundamentals: rapid revenue growth, expanding profitability, a very low debt-to-equity ratio of 0.10, 15% ROE and strong free cash flow that fully backs reported earnings. Valuation adds support, with a moderate 18.2x P/E and a high 5.97% dividend yield. Technicals are constructive, with the stock above its 50-, 100- and 200-day averages, though near-term momentum has flattened into consolidation. Key risks are the projected gross margin compression for 2025, still-modest net margins versus larger healthcare peers, and the prior volatility in cash flow seen in 2023.
M1 Kliniken AG (M12) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 361.82M
- Dividend Yield
- 6.15%
- Average Volume (3M)
- 4,251
- Price to Earnings (P/E)
- 17.9
- Beta (1Y)
- 0.32
- Revenue Growth
- -27.50%
- EPS Growth
- 13.64%
- Country
- Germany
- Employees
- 280
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
M1 Kliniken AG Business Overview & Revenue Model
Company Description
M1 Kliniken AG, a Berlin, Germany-based entity established in 2007 and operating as a subsidiary of MPH Health Care AG, manages medical facilities dedicated to aesthetic and plastic surgery across Germany, Austria, the Netherlands, Switzerland, the U...
How the Company Makes Money
M1 Kliniken AG generates revenue mainly from two business areas. (1) Aesthetics/clinic operations: The company earns money by providing aesthetic medical treatments directly to patients in its clinic network. Revenue is recognized from patient-paid p...
M1 Kliniken AG Financial Statement Overview
Summary
Blending the Income Statement (72), Balance Sheet (78) and Cash Flow (76) scores, M1 Kliniken shows a strong growth and deleveraging profile. Revenue has more than doubled since 2020 to an estimated €364M in 2025, net income rose from €4.3M (2022) to €16M (2024) with €22.1M projected for 2025, and margins have expanded (net margin 1.5% to 4.7%). The balance sheet is conservative, with debt cut to €10.3M, a debt-to-equity ratio of 0.10, equity near 63% of assets and ROE improving to 15.1%. Cash generation is robust, with operating cash flow of €30.5M in 2024 and free cash flow closely tracking net income, confirming earnings quality. Offsetting factors include still-moderate net margins for the healthcare sector, apparent gross profit compression in the 2025 projection despite higher revenue, and the one-off cash flow dip in 2023.
Income Statement
72PositiveBalance Sheet
78PositiveCash Flow
76Positive| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 257.36M | 364.30M | 339.18M | 316.32M | 285.29M | 314.61M |
| Gross Profit | 47.67M | 47.43M | 63.60M | 32.47M | 21.72M | 26.06M |
| EBITDA | 36.64M | 40.49M | 33.38M | 21.79M | 16.07M | 19.78M |
| Net Income | 20.23M | 22.13M | 16.02M | 10.27M | 4.32M | 8.91M |
Balance Sheet | ||||||
| Total Assets | 177.40M | 189.29M | 187.87M | 212.95M | 197.02M | 198.11M |
| Cash, Cash Equivalents and Short-Term Investments | 60.50M | 42.00M | 23.69M | 22.76M | 47.50M | 49.12M |
| Total Debt | 5.90M | 10.26M | 10.42M | 17.04M | 19.67M | 30.93M |
| Total Liabilities | 25.14M | 39.28M | 53.65M | 69.73M | 53.97M | 58.21M |
| Stockholders Equity | 124.18M | 119.93M | 106.10M | 113.25M | 95.52M | 95.03M |
Cash Flow | ||||||
| Free Cash Flow | 23.08M | 37.84M | 29.55M | 6.80M | 19.25M | 14.32M |
| Operating Cash Flow | 23.29M | 37.95M | 30.55M | 7.81M | 21.02M | 15.66M |
| Investing Cash Flow | 22.41M | -645.81K | -5.67M | -9.36M | -1.77M | 213.19K |
| Financing Cash Flow | -13.07M | -13.41M | -30.44M | -14.81M | -21.97M | 4.03M |
M1 Kliniken AG Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:M12, the sentiment is Positive. The current price of 19.50 is above the 20-day moving average (MA) of 19.36, below the 50-day MA of 19.83, and above the 200-day MA of 17.47, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 50.29 is Neutral, neither overbought nor oversold. The STOCH value of 57.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:M12.
M1 Kliniken AG Peers Comparison
Overall Rating
DE:M1273Outperform
DE:LIK67Neutral
DE:FRE63Neutral
DE:MED62Neutral
DE:RHK61Neutral
DE:MAK27Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | EUR 343.00M | 17.89 | 16.58% | 6.15% | -27.50% | 13.64% | |
| 67Neutral | EUR 177.00M | 31.93 | 22.18% | 1.69% | 35.46% | 17.88% | |
| 63Neutral | EUR 28.87B | 18.49 | 7.83% | 2.03% | 6.52% | 35.52% | |
| 62Neutral | EUR 249.38M | 7.98 | 11.94% | 0.76% | 0.77% | -11.41% | |
| 61Neutral | EUR 970.61M | 22.66 | 3.16% | 1.38% | 3.54% | 11.21% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 27Underperform | EUR 17.51M | -1.28 | 16.80% | ― | 2.73% | -1.80% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:M12 | M1 Kliniken AG | 19.50 | 4.63 | 31.18% | |
| DE:FRE | Fresenius SE & Co. KGaA | 51.78 | 6.11 | 13.38% | |
| DE:MED | MEDICLIN AG | 5.25 | 1.89 | 56.06% | |
| DE:RHK | RHON-KLINIKUM AG | 14.50 | 2.50 | 20.79% | |
| DE:MAK | MATERNUS-Kliniken AG | 0.83 | -0.22 | -20.48% | |
| DE:LIK | Limes Schlosskliniken AG | 590.00 | 248.63 | 72.83% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 10, 2026
